Exchange: OTC·Updated 11:37 AM EST

BVNRY ADRs for Bavarian Nordic

$11.73
$0.07
(0.59%)
Today
EarningsMar 11
Mkt Cap$2.66B
Vol7,284.00

About BVNRY

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
50

Neutral Sentiment

How do you feel about BVNRY?

Advertisement|Remove ads.